Centiva Capital LP Invests $398,000 in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Centiva Capital LP acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 26,473 shares of the company's stock, valued at approximately $398,000. Centiva Capital LP owned about 0.06% of Pacira BioSciences at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Innealta Capital LLC acquired a new position in Pacira BioSciences during the second quarter worth approximately $50,000. nVerses Capital LLC boosted its position in Pacira BioSciences by 800.0% during the second quarter. nVerses Capital LLC now owns 1,800 shares of the company's stock worth $51,000 after purchasing an additional 1,600 shares during the period. Quest Partners LLC acquired a new position in shares of Pacira BioSciences in the second quarter valued at $113,000. Canada Pension Plan Investment Board bought a new position in shares of Pacira BioSciences in the second quarter valued at about $140,000. Finally, CWM LLC raised its position in shares of Pacira BioSciences by 713.6% in the third quarter. CWM LLC now owns 6,517 shares of the company's stock valued at $98,000 after purchasing an additional 5,716 shares during the period. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX traded up $0.67 during midday trading on Tuesday, hitting $19.76. The stock had a trading volume of 836,108 shares, compared to its average volume of 854,818. The company's 50-day moving average price is $17.03 and its 200-day moving average price is $19.17. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $35.95. The company has a market capitalization of $912.32 million, a P/E ratio of -9.73 and a beta of 0.80.

Wall Street Analysts Forecast Growth

PCRX has been the topic of several research analyst reports. Truist Financial cut shares of Pacira BioSciences from a "buy" rating to a "sell" rating and lowered their price target for the company from $30.00 to $8.00 in a report on Tuesday, August 13th. Raymond James lowered Pacira BioSciences from an "outperform" rating to a "market perform" rating in a research note on Monday, August 12th. JPMorgan Chase & Co. restated an "underweight" rating and issued a $10.00 price target (down from $45.00) on shares of Pacira BioSciences in a research note on Monday, August 12th. HC Wainwright reiterated a "buy" rating and set a $39.00 price objective on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Finally, Royal Bank of Canada boosted their target price on shares of Pacira BioSciences from $15.00 to $16.00 and gave the company a "sector perform" rating in a research report on Thursday, November 7th. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Pacira BioSciences currently has an average rating of "Hold" and an average target price of $23.50.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.